Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CEO INTERVIEW: JOHN CASTELLO - XOMA LTD (XOMA).


(PAL226) JOHN CASTELLO - XOMA LTD LTD 1 Laron-type dwarfism 2 Leukotriene D 3 Long-term depression, see there 4. Long-term disability  (XOMA). Describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward. Sector: Biotechnology. Published date 6/2/02. Tickers featured: XOMA. Complete text approximately 3000 words. Document # PAL226.

CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7433. Fax: (212) 668-9842. E-mail: transcript@twst.com.

***
COPYRIGHT 2002 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:CEO INTERVIEW: JOHN CASTELLO - XOMA LTD (XOMA).(Brief Article)
Publication:Wall Street Transcript Digest
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 10, 2002
Words:88
Previous Article:[0] CEO INTERVIEW: UNA RYAN - AVANT IMMUNOTHERAPEUTICS INC (AVAN).
Next Article:CEO INTERVIEW: VIJAY SAMANT - VICAL INCORPORATED (VICL).
Topics:



Related Articles
Allergan Returns rBPI Ophthalmic Development Rights to XOMA.
XOMA Presents Corporate Update At Tucker Anthony Sutro Conference.
XOMA STARTS PHASE II TRIAL OF NEUPREX IN CROHN'S DISEASE.
CEO INTERVIEW: JOHN CASTELLO - XOMA LTD (XOMA).
MorphoSys and XOMA cross-license antibody technologies.
XOMA Expands Claims Against Biosite; Alleges that Biosite is Misleading the Public and that its 'New' Technology Willfully Infringes XOMA's Patents.
CEO INTERVIEW: STEVEN B. ENGLE - XOMA LTD. (XOMA).

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles